Trending Now

Important medical research and remarkable case reports worth knowing.

Selected from high-relevance medical literature published in the last 14 days.

AllClinical ResearchCase Reports
FeaturedClinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

N Engl J MedOct 15, 2026

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

Why it matters

The trial provides randomized evidence that a chemotherapy-free combination of a tyrosine kinase inhibitor and immunotherapy can improve event-free survival compared with an imatinib–chemotherapy regimen in adults with…

Read summary

Also worth knowing

Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchHematology

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.

This systematic review and reconstructed individual patient data meta-analysis assessed whether leukemia stem cell (LSC) measurements predict outcomes in patients with acute myeloid leukemia at diagnosis or in…

Blood AdvOct 15, 2026Read summary
Clinical ResearchHematology

The role of allogeneic hematopoietic stem cell transplantation in adults with mature T-cell lymphomas.

This Cochrane systematic review and meta-analysis assessed allogeneic stem cell transplantation (alloSCT) for adults with mature T-cell lymphomas (MTCL), as first-line or salvage treatment.

Cochrane Database Syst RevOct 21, 2026Read summary
Clinical ResearchHematology

TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

TRANSFORM-1 was a multicentre, randomised phase 3 trial comparing navitoclax plus ruxolitinib with placebo plus ruxolitinib in Janus kinase inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis.

BloodOct 15, 2026Read summary
Clinical ResearchHematologyOpen access

Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.

The multicenter randomized RuxoBEAT trial compared first-line ruxolitinib (RUX) with best available therapy (BAT) in patients with polycythemia vera.

Blood Cancer JOct 22, 2026Read summary
Clinical ResearchPediatrics

Ruxolitinib for the treatment of pediatric acute and chronic steroid-refractory graft-versus-host disease: Efficacy, safety, and outcomes.

This single-center retrospective study assessed ruxolitinib in children under 18 years with steroid-refractory graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Hematol Oncol Stem Cell TherOct 21, 2026Read summary
Clinical ResearchOncology (Medical)

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial.

The multicenter phase 1/2 CRC01-01 trial evaluated anbalcabtagene autoleucel, a CD19 CAR T-cell therapy with PD-1 and TIGIT knockdown, in patients with relapsed or refractory large B-cell lymphoma.

BloodOct 22, 2026Read summary
Clinical ResearchHematologyOpen access

The perceptions of hematopoietic stem cell transplantation decision-making in patients with hematologic malignancies: a qualitative systematic review.

This qualitative systematic review synthesized research on how patients with hematologic malignancies perceive decisions about hematopoietic stem cell transplantation (HSCT).

Support Care CancerOct 23, 2026Read summary
Clinical ResearchNephrology

Local ancestry-aware genome-wide meta-analysis uncovers novel genetic loci for sickle cell disease nephropathy.

This local ancestry-aware genome-wide association meta-analysis examined estimated glomerular filtration rate in participants from two well-characterized adult sickle cell disease cohorts, seeking genetic loci…

Blood AdvOct 16, 2026Read summary
Clinical ResearchPediatrics

Bacterial infections and antibiotic susceptibility in children with sickle-cell anemia on malaria chemoprevention using Dihydroartemisinin-piperaquine (DP) or Sulfadoxine-pyrimethamine (SP) in Uganda.

This analysis nested within a randomized, double-blind trial assessed bacterial infections and antimicrobial resistance among Ugandan children aged 6 months to 15 years with sickle-cell anemia receiving weekly…

PLoS OneOct 15, 2026Read summary
Clinical ResearchHematology

Non-Relapse Mortality With Bispecific Antibodies in Hematologic Malignancies: A Dual Systematic Review and Pharmacovigilance Analysis.

This systematic review and meta-analysis, supplemented by a pharmacovigilance analysis of FAERS, assessed non-relapse mortality (NRM) and other toxicities with bispecific antibodies in relapsed/refractory hematologic…

Hematol OncolOct 17, 2026Read summary

Showing 12 of 16 publications that cleared our clinical screen in the last 14 days.

Looking for an earlier article?Everything that has appeared in Trending is in the archive.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.